stockportfolio.pro
Stocks / CYTK vs TEM
CYTK vs TEM
Cytokinetics, Incorporated and Tempus AI, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
CYTK is the larger company ($9.1B vs $8.7B). On the fundamentals, TEM grows revenue faster (58.3% vs 9.5%); TEM earns a higher net margin (-19.3% vs -891.6%); CYTK has the stronger return on equity (119.0% vs -49.9%). Full numbers below — the stronger figure on each row is in green.
| Cytokinetics, Incorporated (CYTK) | Tempus AI, Inc. (TEM) | |
|---|---|---|
| Market cap | $9.1B | $8.7B |
| Revenue (latest FY) | $88.04M | $1.27B |
| Net income (latest FY) | $-784.96M | $-245.03M |
| Revenue growth (5y CAGR) | 9.5% | 58.3% |
| Net margin | -891.6% | -19.3% |
| Return on equity | 119.0% | -49.9% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 0 |
| Positive free cash flow | No | No |
Compare with another company:
See the full CYTK vs TEM breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open CYTK's full financials → Open TEM's full financials →More comparisons
Frequently asked questions
Which is bigger, CYTK or TEM?
Cytokinetics, Incorporated is larger by market capitalization — $9.1B versus $8.7B.
Which grows faster, CYTK or TEM?
Over the last five fiscal years, Tempus AI, Inc. grew revenue faster — 58.3%/yr versus 9.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.